Is Tango Therapeutics, Inc. (TNGX) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 1.6% / 30% | 11.3% / 30% | 0.0% / 30% | 18.75% / 5% | ✗ NOT HALAL |
| DJIM | 1.6% / 33% | 11.3% / 33% | 0.0% / 33% | 18.75% / 5% | ✗ NOT HALAL |
| MSCI | 11.5% / 33% | 81.5% / 33% | 0.0% / 33% | 18.75% / 5% | ✗ NOT HALAL |
| S&P | 1.6% / 33% | 11.3% / 33% | 0.0% / 33% | 18.75% / 5% | ✗ NOT HALAL |
| FTSE | 11.5% / 33% | 81.5% / 33% | 0.0% / 50% | 18.75% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | -111.9% | |
| Operating Margin | -178.4% | |
| Net Margin | -162.9% | |
| Return on Equity (ROE) | -37.2% | |
| Return on Assets (ROA) | -19.5% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$139M |
| Free Cash Flow | -$140M |
| Total Debt | $34M |
| Debt-to-Equity | 9.7 |
| Current Ratio | 16.3 |
| Total Assets | $399M |
Price & Trading
| Last Close | $19.86 |
| 50-Day MA | $14.27 |
| 200-Day MA | $9.29 |
| Avg Volume | 3.4M |
| Beta | 1.8 |
|
52-Week Range
$1.03
| |
About Tango Therapeutics, Inc. (TNGX)
Tango Therapeutics, Inc., a precision oncology company, focuses on the discovery and development of drugs in defined patient populations with unmet medical need. The company develops methylthioadenosine -cooperative protein arginine methyltransferase 5 (PRMT5) inhibitors, including TNG462, which is in Phase 1/2 clinical trial for treating pancreatic and lung cancer; and TNG456, a brain-penetrant PRMT5 inhibitor for the treatment of glioblastoma. It is developing TNG260, a co-repressor of repressor element-1 silencing transcription inhibitor to reverse the immune evasion effect of serine-threonine kinase (STK) 11 loss-of-function mutations to treat lung cancer. The company was founded in 2017 and is headquartered in Boston, Massachusetts.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Tango Therapeutics, Inc. (TNGX) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Tango Therapeutics, Inc. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Tango Therapeutics, Inc.'s debt ratio?
Tango Therapeutics, Inc.'s debt ratio is 1.6% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 11.5%.
What are Tango Therapeutics, Inc.'s key financial metrics?
Tango Therapeutics, Inc. has a market capitalization of $2.7B, and revenue of $62M. The company maintains a gross margin of -111.9% and a net margin of -162.9%. Return on equity stands at -37.2%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.